FATE Valuation

Fate Therapeutics Inc

Add to Watchlist

Advanced Chart

1.000

+0.05(5.263%)1D

Overview
Forecast
Valuation
Earnings

FATE Relative Valuation

FATE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, FATE is overvalued; if below, it's undervalued.

Historical Valuation

Fate Therapeutics Inc (FATE) is now in the Fair zone, suggesting that its current forward PS ratio of 18.25 is considered Fairly compared with the five-year average of -11.71. The fair price of Fate Therapeutics Inc (FATE) is between 0.59 to 7.20 according to relative valuation methord.

Relative Value

Fair Zone

0.59-7.20

Current Price：1.01

Fair

-0.84

Trailing

Forward

0.22

EV/EBITDA

Fate Therapeutics Inc. (FATE) has a current EV/EBITDA of 0.22. The 5-year average EV/EBITDA is -7.68. The thresholds are as follows: Strongly Undervalued below -31.32, Undervalued between -31.32 and -19.50, Fairly Valued between 4.14 and -19.50, Overvalued between 4.14 and 15.96, and Strongly Overvalued above 15.96. The current Forward EV/EBITDA of 0.22 falls within the Historic Trend Line -Fairly Valued range.

0.21

EV/EBIT

Fate Therapeutics Inc. (FATE) has a current EV/EBIT of 0.21. The 5-year average EV/EBIT is -9.52. The thresholds are as follows: Strongly Undervalued below -36.41, Undervalued between -36.41 and -22.97, Fairly Valued between 3.92 and -22.97, Overvalued between 3.92 and 17.37, and Strongly Overvalued above 17.37. The current Forward EV/EBIT of 0.21 falls within the Historic Trend Line -Fairly Valued range.

18.25

Fate Therapeutics Inc. (FATE) has a current PS of 18.25. The 5-year average PS is 84.97. The thresholds are as follows: Strongly Undervalued below -64.40, Undervalued between -64.40 and 10.28, Fairly Valued between 159.65 and 10.28, Overvalued between 159.65 and 234.34, and Strongly Overvalued above 234.34. The current Forward PS of 18.25 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Fate Therapeutics Inc. (FATE) has a current P/OCF of 0.00. The 5-year average P/OCF is -14.39. The thresholds are as follows: Strongly Undervalued below -50.93, Undervalued between -50.93 and -32.66, Fairly Valued between 3.88 and -32.66, Overvalued between 3.88 and 22.15, and Strongly Overvalued above 22.15. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-1.29

P/FCF

Fate Therapeutics Inc. (FATE) has a current P/FCF of -1.29. The 5-year average P/FCF is -15.06. The thresholds are as follows: Strongly Undervalued below -52.09, Undervalued between -52.09 and -33.58, Fairly Valued between 3.46 and -33.58, Overvalued between 3.46 and 21.97, and Strongly Overvalued above 21.97. The current Forward P/FCF of -1.29 falls within the Historic Trend Line -Fairly Valued range.

Fate Therapeutics Inc (FATE) has a current Price-to-Book (P/B) ratio of 0.42. Compared to its 3-year average P/B ratio of 1.15 , the current P/B ratio is approximately -63.74% higher. Relative to its 5-year average P/B ratio of 4.52, the current P/B ratio is about -90.77% higher. Fate Therapeutics Inc (FATE) has a Forward Free Cash Flow (FCF) yield of approximately -108.32%. Compared to its 3-year average FCF yield of -56.19%, the current FCF yield is approximately 92.76% lower. Relative to its 5-year average FCF yield of -35.13% , the current FCF yield is about 208.38% lower.

0.42

P/B

Median3y

1.15

Median5y

4.52

-108.32

FCF Yield

Median3y

-56.19

Median5y

-35.13

Competitors Valuation Multiple

The average P/S ratio for FATE's competitors is 10.26, providing a benchmark for relative valuation. Fate Therapeutics Inc Corp (FATE) exhibits a P/S ratio of 18.25, which is 77.82% above the industry average. Given its robust revenue growth of -71.84%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

FATE.O

Fate Therapeutics Inc

Molecular Partners AG

Zentalis Pharmaceuticals Inc

Loss

102.43M

SPRO.O

Spero Therapeutics Inc

Performance Decomposition

Market capitalization of FATE decreased by 72.86% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -567.44 to -1.79K.

The secondary factor is the Revenue Growth, contributed -71.84%to the performance.

Overall, the performance of FATE in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-71.84%

6.77M → 1.91M

Revenue Growth

214.85%

-567.44 → -1.79K

Margin Expansion

-215.87%

0.57 → -0.66

P/E Change

-72.86%